Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery
Notice Number:

Key Dates

Release Date:

December 2, 2021

First Available Due Date:
February 05, 2022
Expiration Date:
January 08, 2025

Related Announcements

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
NOT-AI-22-009 - Notice of Early Expiration of PA-19-077, “Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)


The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants about an area of special interest to NIAID on early phase translational research that will generate new malaria vaccine candidates with desirable features suitable for further downstream development and clinical evaluation. This NOSI encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially Plasmodium falciparum and Plasmodium vivax.

Background and Research Objectives

This NOSI is intended to encourage research to identify, characterize, credential and validate new protective antigens or vaccine candidates with appropriate assay systems or animal models. For purposes of this NOSI, protective antigens or vaccine candidates should demonstrate appropriate functional characteristics, such as prevention of infection, amelioration of disease, interruption of transmission, or prevention of relapse, or other functional features, when applicable.

Examples of research topics include, but are not limited to:

  • Identifying, characterizing, credentialing and/or validating novel protective malaria antigens/peptides/epitopes;
  • Structure-based immunogen design and testing;
  • Discovery of new effective vaccines utilizing novel technology platforms, adjuvants, or vaccine strategies;
  • Construction of novel and improved whole organism-based malaria vaccines;
  • Discovery of novel vaccine candidates or formulations that exhibit improved functionality or manufacturability;
  • Discovery or improvement of vaccine candidates with favorable storage conditions, or administration and deployment features;
  • Screening, testing, credentialing and/or validating new vaccine candidates or formulations with novel assays or animal models.

Application and Submission Information

This notice applies to application receipt dates on or after February 5, 2022 and subsequent receipt dates through January 7, 2025.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements.

  • PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include "NOT-AI-22-014" (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.


Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Scientific/Research Contact(s)

Annie Mo, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3320

Financial/Grants Management Contact(s)

Vandhana Khurana
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-2966